Dipyridamole
Dipyridamole is a non-selective inhibitor of phosphodiesterases (PDEs) that increases levels of cAMP and cGMP; it also inhibits adenosine deaminase. Dipyridamole exhibits vasodilatory, ati-thrombotic, and anti-inflammatory activities. In monocytes, dipyridamole decreases expression of matrix metalloproteinase 9 (MMP9) by inhibiting TNF-α-induced NF-κB activation, degradation of IkBα, and activation of p38 MAPK. Dipyridamole also inhibits vascular stenosis by suppressing proliferation of venous and arterial smooth muscle cells.
References PubMed ID::http://www.ncbi.nlm.nih.gov/pubmed/18883375
Cas No. |
58-32-2 |
---|---|
Purity |
≥98% |
Formula |
C24H40N8O4 |
Formula Wt. |
504.63 |
Chemical Name |
2,2,2,2-[(4,8-Di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakisethanol |
IUPAC Name |
2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol |
Synonym |
Anginal; Cardoxin; Coridil; Dipyridan; Gulliostin; Natyl; Persantine; Piroan; Protangix |
Melting Point |
163°C |
Solubility |
Soluble in methanol, chloroform and ethanol. Slightly soluble in water. |
Appearance |
A Bright Yellow Crystalline Powder |
Massaro M, Scoditti E, Carluccio MA, et al. Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes. Thromb Haemost. 2013 Feb;109(2):280-9. PMID: 23238437.
Alberts MJ. Antithrombotic therapy for secondary stroke prevention. Continuum (Minneap Minn). 2011 Dec;17(6 2ndary Stroke Prevention):1255-66. PMID: 22810029.
Zhuplatov SB, Masaki T, Blumenthal DK, et al. Mechanism of dipyridamoles action in inhibition of venous and arterial smooth muscle cell proliferation. Basic Clin Pharmacol Toxicol. 2006 Dec;99(6):431-9. PMID: 17169124.